A once-daily pill known as orforglipron produced greater weight loss and better blood sugar control than the leading oral version of semaglutide in a large head-to-head clinical trial, according to results that could reshape treatment for type 2 diabetes and obesity. The findings, from the ACHIEVE-3 study, were published in the medical journal The Lancet and reported this week.
The drug belongs to the class known as GLP-1 receptor agonists, the same family that includes widely used injectable medicines for diabetes and weight loss. Unlike most of those treatments, orforglipron is a small molecule that can be taken as a tablet without food or water restrictions, a feature that experts say could make effective therapy far easier to manufacture and distribute at scale.
The 52-week trial enrolled 1,698 adults with type 2 diabetes whose condition was inadequately controlled with metformin, dividing them across four treatment arms comparing two doses of orforglipron with two doses of oral semaglutide. Participants taking the highest dose of orforglipron lost an average of 19.7 pounds, or 9.2 percent of body weight, compared with 11.0 pounds, or 5.3 percent, among those on the higher semaglutide dose, a relative difference of roughly 74 percent.
Beyond weight and glucose control, the pill delivered clinically meaningful improvements across several cardiovascular risk factors, including reductions in total cholesterol, non-HDL cholesterol, triglycerides and systolic blood pressure. Researchers reported that benefits began to appear as early as four weeks into treatment and were sustained throughout the study, with orforglipron outperforming its comparator on the primary endpoint and all key secondary measures.
The results carry significant implications for global access to obesity and diabetes care, given that an oral therapy could sidestep the manufacturing bottlenecks and cold-chain requirements associated with injectable drugs. The manufacturer, Eli Lilly, said it had submitted orforglipron to regulators in more than 40 countries, with a potential decision on its use for obesity in the United States anticipated during the current year.
Specialists cautioned that side effects typical of the drug class, such as nausea and other gastrointestinal symptoms, will require continued monitoring, and that longer-term data on safety and durability remain to be gathered. Even so, many described the head-to-head comparison as an important marker of how quickly the field of weight-loss medicine is advancing toward more convenient, pill-based options.
Comments